Login to Your Account



BIO INVESTOR FORUM

Gene therapy advances beyond first era setbacks, but challenges remain

By Karen Pihl-Carey
Staff Writer

Wednesday, October 8, 2014
SAN FRANCISCO – The 2012 European approval of Uniqure BV's Glybera has sparked a renewal of interest in gene therapy, a field that was marred by a serious setback in 1999 that proved fatal for a patient.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription